PND19 A LONG-TERM COST-EFFECTIVENESS MARKOV MODEL COMPARING DISEASE MODIFYING TREATMENTS IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY

Cost-effectiveness of Four Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis: A Markov Model Based on Long-term Clinical Data

Journal of Managed Care Pharmacy ◽

10.18553/jmcp.2007.13.3.245 ◽

2007 ◽

Vol 13 (3) ◽

pp. 245-261 ◽

Cited By ~ 20

Author(s):

Christopher Bell ◽

Jonathan Graham ◽

Stephanie Earnshaw ◽

MerriKay Oleen-Burkey ◽

Jane Castelli-Haley ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Markov Model ◽

Clinical Data ◽

Model Based ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Immunomodulatory Therapies

Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review

PLoS ONE ◽

10.1371/journal.pone.0231722 ◽

2020 ◽

Vol 15 (6) ◽

pp. e0231722 ◽

Cited By ~ 1

Author(s):

Rosa C. Lucchetta ◽

Letícia P. Leonart ◽

Marcus V. M. Gonçalves ◽

Jefferson Becker ◽

Roberto Pontarolo ◽

...

Keyword(s):

Multiple Sclerosis ◽

Systematic Review ◽

Clinical Studies ◽

Relapsing Remitting ◽

Disease Modifying ◽

The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis

Journal of Medical Economics ◽

10.1080/13696998.2016.1258366 ◽

2016 ◽

Vol 20 (3) ◽

pp. 297-302 ◽

Cited By ~ 12

Author(s):

Duygu Bozkaya ◽

Terrie Livingston ◽

Kristen Migliaccio-Walle ◽

Tanner Odom

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Cost ◽

The Impact of Neutralizing Antibody Testing on The Cost-Effectiveness of Injectable Disease Modifying Treatments for Relapsing Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2015.03.1657 ◽

2015 ◽

Vol 18 (3) ◽

pp. A284

Author(s):

M Andreykiv ◽

A Plich ◽

A Prüfert ◽

L Heemstra ◽

A Van Engen

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Neutralizing Antibody ◽

Antibody Testing ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Cost ◽

Relapsing Remitting Multiple Sclerosis ◽

The Impact

Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis

Journal of Medical Economics ◽

10.1080/13696998.2016.1247712 ◽

2016 ◽

Vol 20 (3) ◽

pp. 228-238 ◽

Cited By ~ 10

Author(s):

Luis Hernandez ◽

Shien Guo ◽

Hector Toro-Diaz ◽

Stuart Carroll ◽

Syed Feisal Syed Farooq

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

PNL8 ASSESSING THE COST-EFFECTIVENESS OF IMMUNOMODULATORYTHERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS BASED ON LONG-TERM DATA

Value in Health ◽

10.1016/s1098-3015(10)64557-3 ◽

2006 ◽

Vol 9 (3) ◽

pp. A81-A82

Author(s):

CF Bell ◽

JB Graham ◽

SR Earnshaw ◽

M Oleen-Burkey ◽

J Castelli-Haley ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Relapsing Remitting ◽

The Cost ◽

Relapsing Remitting Multiple Sclerosis ◽

Term Data

The Cost-Effectiveness of Disease Modifying Therapies for The Treatment of Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2015.03.1653 ◽

2015 ◽

Vol 18 (3) ◽

pp. A283 ◽

Cited By ~ 2

Author(s):

D. Bozkaya ◽

T.P. Livingston ◽

K. Migliaccio-Walle ◽

S. Mehta ◽

T. Odom

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Cost ◽

Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis

Journal of Managed Care Pharmacy ◽

10.18553/jmcp.2011.17.5.377 ◽

2011 ◽

Vol 17 (5) ◽

pp. 377-381 ◽

Cited By ~ 3

Author(s):

Russell V. Becker III ◽

Carole Dembek

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Disease Modifying Drugs ◽

Effectiveness Analysis ◽

Cohort Selection ◽

Relapsing Remitting ◽

Disease Modifying ◽

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

PharmacoEconomics ◽

10.2165/00019053-200826070-00008 ◽

2008 ◽

Vol 26 (7) ◽

pp. 617-627 ◽

Cited By ~ 54

Author(s):

Ray Gani ◽

Gavin Giovannoni ◽

David Bates ◽

Belinda Kemball ◽

Steve Hughes ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Highly Active ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Uk ◽

PND13 - REAL WORLD EVIDENCE (RWE) ON IMPACT OF AGE ON LONG-TERM PERSISTENCE TO DISEASE MODIFYING THERAPIES (DMTS) IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN AUSTRALIA

Value in Health ◽

10.1016/j.jval.2018.09.1980 ◽

2018 ◽

Vol 21 ◽

pp. S331

Author(s):

M Schulz ◽

B Arora ◽

T Spelman ◽

R Walker ◽

S Verhaeghe ◽

...

Keyword(s):

Multiple Sclerosis ◽

Real World ◽

Real World Evidence ◽

Relapsing Remitting ◽

Disease Modifying ◽